6PGD Upregulation is Associated with Chemo- and Immuno-Resistance of Renal Cell Carcinoma via AMPK Signaling-Dependent NADPH-Mediated Metabolic Reprograming.

CONCLUSIONS: Our work provides preclinical evidence that 6PGD inhibition may represent a potential therapeutic strategy to augment the efficacy of RCC standard of care drugs.
PMID: 32829780 [PubMed - in process]

Source: The American Journal of the Medical Sciences - August 26, 2020 Category: General Medicine Authors: Cao J, Sun X, Zhang X, Chen D Tags: Am J Med Sci Source Type: research